April – June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
Signals of Serious Risks (FAERS)
Expert: Pharmacists Play Key Role in Expanding RSV Vaccine Awareness, Adult Immunization Efforts
Alyssa Modic, PharmD, discusses the evolving role of pharmacists in adult immunizations and strategies to improve respiratory syncytial virus (RSV)…
Updated Diabetes Guidelines Prioritize SGLT-2 and GLP-1 Medications to Reduce Cardiovascular, Kidney Risk
An international BMJ panel recommended broader use of SGLT-2 inhibitors and GLP-1 receptor agonists.
Hans Kissle LLC Issues Allergy Alert on Undeclared Wheat (Allergen) in Hans Kissle Red Potato Bliss Salad
Haverhill, MA — Hans Kissle is voluntarily recalling 120 units of Hans Kissle Red Potato Bliss Salad due to undeclared…
FDA Approves 3-Month Leuprolide Mesylate 21 mg Formulation for Advanced Prostate Cancer
The FDA has approved a ready-to-use long-acting injectable formulation that is administered every 3 months as a treatment for advanced…
Many Patients With Statin Intolerance Self-Medicate, Despite No Link to Lowering LDL-C
Self-medication, including the use of dietary supplements and pain relief drugs, were reported by many patients with statin-associated muscle symptoms…
FluMist Home Delivery Expands Access to Seasonal Influenza Vaccination
FluMist Home, the first at-home nasal spray flu vaccine, is now available for direct delivery to patients in 34 US…
The Role of LAIs in Schizophrenia: Convenience, Adherence, and Access
Explore the benefits and challenges of long-acting injectables (LAIs) in managing schizophrenia for improved patient outcomes.
Therapeutic Response with Genialis – Life Sciences Today Podcast Episode 24
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest…
Iza-Bren Receives FDA Breakthrough Therapy Designation for EGFR-Mutated NSCLC
The action is supported by 3 ongoing clinical trials, which are evaluating izalontamab brengitecan (iza-bren) in non–small cell lung cancer…